Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) insider Greg Keenan sold 8,305 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $8.23, for a total transaction of $68,350.15. Following the completion of the sale, the insider now directly owns 153,484 shares of the company's stock, valued at $1,263,173.32. This represents a 5.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Greg Keenan also recently made the following trade(s):
- On Monday, March 3rd, Greg Keenan sold 12,239 shares of Aurinia Pharmaceuticals stock. The shares were sold at an average price of $8.00, for a total transaction of $97,912.00.
Aurinia Pharmaceuticals Trading Down 0.5 %
Shares of AUPH opened at $8.15 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. Aurinia Pharmaceuticals Inc. has a 1 year low of $4.71 and a 1 year high of $10.67. The company has a 50 day simple moving average of $8.08 and a two-hundred day simple moving average of $7.87. The firm has a market cap of $1.17 billion, a P/E ratio of -54.33 and a beta of 1.22.
Analyst Ratings Changes
Separately, StockNews.com lowered shares of Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Wednesday, February 19th.
View Our Latest Stock Report on Aurinia Pharmaceuticals
Institutional Trading of Aurinia Pharmaceuticals
A number of institutional investors have recently bought and sold shares of the stock. Invesco Ltd. lifted its position in Aurinia Pharmaceuticals by 1.0% in the fourth quarter. Invesco Ltd. now owns 144,112 shares of the biotechnology company's stock worth $1,294,000 after buying an additional 1,421 shares during the last quarter. Bridgefront Capital LLC lifted its position in Aurinia Pharmaceuticals by 12.9% in the fourth quarter. Bridgefront Capital LLC now owns 16,606 shares of the biotechnology company's stock worth $149,000 after buying an additional 1,891 shares during the last quarter. Cetera Investment Advisers lifted its position in Aurinia Pharmaceuticals by 3.2% in the fourth quarter. Cetera Investment Advisers now owns 64,638 shares of the biotechnology company's stock worth $580,000 after buying an additional 2,000 shares during the last quarter. Teacher Retirement System of Texas lifted its position in Aurinia Pharmaceuticals by 5.9% in the fourth quarter. Teacher Retirement System of Texas now owns 36,098 shares of the biotechnology company's stock worth $324,000 after buying an additional 2,020 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in Aurinia Pharmaceuticals by 368.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock worth $30,000 after buying an additional 2,635 shares during the last quarter. 36.83% of the stock is currently owned by institutional investors.
About Aurinia Pharmaceuticals
(
Get Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
